Huluwa ST葫芦娃
9 significant filings since 29 May 2026: 3 on regulatory action, 2 on regulatory inquiry and 1 on share pledge, and 3 other kinds. The latest, on 15 Aug 2026: 海南葫芦娃药业集团股份有限公司关于收到海南证监局警示函的整改报告. On 15 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to fall by 4,166.73% to 4,996.67% from the same period a year earlier.
自 29 May 2026 起有 9 份重大公告：regulatory action 3 份、regulatory inquiry 2 份、share pledge 1 份，另有 3 类。最新一份（15 Aug 2026）：海南葫芦娃药业集团股份有限公司关于收到海南证监局警示函的整改报告。15 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期下降 4,166.73% 至 4,996.67%。
No broker reports from the last twelve months are held for this company. Brokers covered 1,185 of the 2,361 SSE listings (50%) over the same period. 近十二个月无本公司研报；同期券商覆盖了 2,361 只 SSE 证券中的 1,185 只（50%）。
No broker has changed its rating on this company in the reports held.